The 2021 Genitourinary (GU) Cancers Symposium, one of the largest conference in genitourinary cancers will be held virtually February 11 to 13, showcasing practice-changing research, diverse speakers, global perspectives, and...
Read MoreTreatment with apalutamide Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer Final analysis from Phase 3 TITAN study demonstrated apalutamide provided statistically...
Read MoreIn high-risk muscle-invasive urothelial carcinoma, the use of nivolumab after surgery cut patients’ risk of disease returning or death by 30% over placebo. The data was released for presentation at the American Society of...
Read MoreResults from a retrospective analysis evaluating (cabozantinib) activity in brain metastases in patients with renal cell carcinoma (RCC) will be presented as part of the Poster Session: Renal Cell Cancer at the 2021 American...
Read More
It’s no question that advancements in the treatment of hyperlipidemia were in the spotlight...
Read MoreAAO Macular Degeneration Conference Report.indd Featuring Brolucizumab forWet AMD: Assessing Profiles & Early Outcomes Cataract Surgery inWet AMD: Assessing Outcomes & Complications Assessing a Novel Contrast Sensitivity...
Read More[flippingbook width=”100%” height=”auto” ratio=”3:2″ title=”Verzenio – MonarchE”]https://online.flippingbook.com/view/449874131/[/flippingbook] In an extended analysis of the...
Read MoreCertain patients with luminal early breast cancer and up to 3 involved lymph nodes can be treated with adjuvant endocrine therapy alone, according to the primary outcome analysis of the ADAPT HR+/HER2- trial (NCT01779206),...
Read MoreThank you for taking our quiz on allergic asthma! How did you do? 1) What percent of patients diagnosed with severe asthma (mean age of 12 years) were drug adherent, according to a study presented at AAAAI? a) 43% b) 57% c) 68%...
Read MoreThank you for taking our quiz on chronic urticaria! How did you do? 1) The NCBI recently released recommendations for diagnosis and management of chronic idiopathic urticaria, recommends using a skin prick test as part of...
Read More1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC: a) pembrolizumab or...
Read MoreIn an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...
Read MoreIn an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer taking antibody-drug conjugate trastuzumab deruxtecan continued to demonstrate favorable efficacy data, durable...
Read More
Researchers conducted a study to assess the medical and clinical changes patients with rheumatoid...
Read More
Psoriatic arthritis (PsA) is a heterogeneous disease which may precede, occur concurrently, or...
Read More
Despite numerous effective therapies for patients with psoriatic arthritis (PsA), many do not...
Read More
Guselkumab (GUS), a fully human monoclonal antibody, selectively binds and blocks IL-23. VOYAGE 1...
Read More
Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A....
Read MorePhysician’s Weekly spoke with first author Nicholas A. Marston, MD, an Associate Physician in the Cardiovascular Division at Brigham and Women’s Hospital (Boston, USA), an Instructor of Medicine at Harvard Medical School, and an...
Read MoreHBM9036 ophthalmic solution 0.25%, also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...
Read More
